Vera Therapeutics, Inc.

Vera Therapeutics, Inc. announced alignment with the U.S. Food and Drug Administration (FDA) on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in adults with IgA Nephropathy (IgAN). The eGFR results are now expected in Q3 2026, pulled forward from 2027. Pending positive results, the company plans to submit a supplemental Biologics License Application (sBLA) for full approval in Q4 2026, with potential full approval in 2027. The Prescription Drug User Fee Act (PDUFA) date for accelerated approval of atacicept is July 7, 2026.

Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards to ten new employees on May 4, 2026. These awards include non-qualified stock options to purchase 40,250 shares and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock. The awards were approved as a material inducement for employment under the company's 2024 Inducement Plan. The stock options have an exercise price of $35.51 per share and both stock options and RSUs will vest over four years, subject to continued employment.

Vera Therapeutics reported a significant increase in net loss for the first quarter of 2026, reaching $121.0 million, compared to $51.7 million in the same period of 2025. This was primarily driven by a substantial rise in research and development and general and administrative expenses. While cash and cash equivalents decreased, marketable securities increased, bringing total liquidity to $596.8 million, which management believes is sufficient for at least the next 12 months. The company continues to incur net operating losses and expects to raise additional capital to fund its long-term objectives.

Vera Therapeutics announced its Q1 2026 financial results and significant business updates. The U.S. FDA granted priority review to its Biologics License Application (BLA) for atacicept in IgA Nephropathy (IgAN), setting a PDUFA date of July 7, 2026. The company is on track for a U.S. commercial launch of atacicept in mid-2026, pending regulatory approval, and expects its strong balance sheet to fund operations beyond the launch. The company reported an increased net loss for the quarter.

Vera Therapeutics, Inc. announced that its management team will present at the Bank of America Securities 2026 Health Care Conference on May 13, 2026, at 4:20 PM PDT. The team will also hold one-on-one investor meetings. The company is focused on developing treatments for serious immunological diseases, with lead product candidate atacicept for IgA nephropathy and lupus nephritis, and other candidates VT-109 and MAU868 in its pipeline.

Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards to 89 new employees on April 8, 2026. The awards consist of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock. These awards were approved as a material inducement for employment under the company's 2024 Inducement Plan and will vest over four years.